Sasol Ltd. American Depositary Shares vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Sasol Ltd. American Depositary Shares trades at $15.05 (market cap $9.25B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 6.3× Sasol Ltd. American Depositary Shares's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.36% dividend while Sasol Ltd. American Depositary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sasol Ltd. American Depositary Shares for 0 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| SSL | TAK | |
|---|---|---|
Market Cap | $9.25B | $58.16B |
Volume | 1,222,173 | 2,467,530 |
Sector | Basic Materials | Health |
52-Week High | $15.14 | $19.05 |
52-Week Low | $5.33 | $13.23 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $12.97B | $86.04B |
Dividend Yield | — | 3.36% |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Sasol Limited is a Johannesburg-headquartered chemicals and energy company that uses its proprietary Fischer-Tropsch technology to convert coal, natural gas, and crude-oil feedstocks into fuels and chemical products such as polymers, solvents, surfactants, and ammonia, with operations across Southern Africa and international chemical manufacturing sites, including in US.
Read more on SSL →Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →